Early detection of prostate cancer : results of a prostate specific a antigen-based detection program in Japan.
Prostate cancer increasingly is becoming a medical problem in Japan.
To maximize the chance for cure, extensive effort is being made to detect prostate cancer while confined to the gland.
Determination was made of serum prostate specific antigen (PSA) in the early detection of prostate cancer in an Asian male population aged 55 years or older.
Recommendation for biopsy was based solely on this parameter when its value exceeded 2.0 ng/ml in IMx immunoenzymetric assay.
Of 1189 men, 150 (12.6%) had elevated values.
The proportion of males with serum PSA greater than 4.0 ng/ml was only 3.4%. Of the 99 males who underwent ultrasound-guided biopsies, 16 cancers were detected, a cancer detection rate of 1.3%. Most of these (81.3%) were clinically localized cancers.
Elderly Asian males appear to have lower serum PSA than their Western counterparts.
The optimal cutoff of serum PSA for early detection should be examined further in Asian male populations.
Differences in the incidence of prostate cancer between ethnic groups may have been overestimated in previous studies owing in part to unawareness by the physician and general public.
Though the frequent use of more sophisticated diagnostic modalities will likely disclose greater numbers of prostate cancers in Japan, whether early detection reduces mortality by minimizing risk of death from cancer remains a point to be determined.
Mots-clés Pascal : Tumeur maligne, Prostate, Homme, Diagnostic, Antigène associé tumeur, Marqueur tumoral, Sérum, Seuil, Spécificité, Sensibilité, Programme sanitaire, Japon, Asie, Mongoloïde, Dépistage, Stade précoce, Appareil génital mâle pathologie, Appareil urinaire pathologie, Prostate pathologie, Antigène spécifique prostate, Valeur prédictive
Mots-clés Pascal anglais : Malignant tumor, Prostate, Human, Diagnosis, Tumor associated antigen, Tumoral marker, Serum, Threshold, Specificity, Sensitivity, Sanitary program, Japan, Asia, Mongoloid, Medical screening, Early stage, Male genital diseases, Urinary system disease, Prostate disease, Prostate specific antigen, Predictive value
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0473611
Code Inist : 002B14D02. Création : 01/03/1996.